Dailypharm Live Search Close

AZ has applied for domestic approval of COVID-19 vaccine

By Lee, Tak-Sun | translator Choi HeeYoung

21.01.04 14:21:25

°¡³ª´Ù¶ó 0
Clinical data conducted in the UK and Brazil were submitted, under the condition of two doses of 18 years of age or older



The MFDS announced today (4th) that AstraZeneca Korea's application for item approval for COVID-19 vaccine (code name: AZD1222) has been received. This vaccine is a 'viral vector vaccine' manufactured by putting COVID-19 surface antigen gene into a chimpanzee adenovirus vector.

Viral vector vaccines are manufactured by inserting viral antigen genes that cause infectious diseases into other viral genes used as carriers and mass-producing them.

AstraZeneca vaccine uses adenovirus, which only infects chimpanzees, as a carrier to deliver COVID-19 surface antigen gene into human cells, and the delivered COVID-19 antigen gene synthesizes antigen proteins in the body to induce the production of

Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)